Use of Pulmonary Arterial Hypertension–Approved Therapy in the Treatment of Non–Group 1 Pulmonary Hypertension at US Referral Centers
Open Access
- 1 June 2015
- journal article
- research article
- Published by Wiley in Pulmonary Circulation
- Vol. 5 (2), 356-363
- https://doi.org/10.1086/681264
Abstract
Pulmonary hypertension (PH) is a frequent complication of left heart disease and parenchymal lung disease, and it portends increased mortality. A growing number of medications are approved for the treatment of World Health Organization (WHO) group 1 pulmonary arterial hypertension (PAH). However, they are not well studied in PH of other etiologies (WHO groups 2–5). We sought to assess treatment approaches used by PAH referral centers in this diverse group of patients. We developed a semiquantitative online survey designed to evaluate the use of PAH-approved therapy by pulmonary vascular disease centers in the United States for management of non–group 1 PH. Thirty of 50 centers completed the survey. Almost all centers (93%) reported using PAH therapy for patients with non–group 1 PH, including 77% with group 2 PH and 80% with group 3 PH. Elevated transpulmonary gradient or pulmonary vascular resistance and the presence of right ventricular (RV) dysfunction were commonly cited as supporting use of PAH therapy in patients with PH secondary to left heart disease. For patients with PH and concomitant parenchymal lung disease, degree of pulmonary function impairment and RV dysfunction were most important in influencing use of PAH therapy. In conclusion, pulmonary vascular disease treatment centers use PAH-approved therapy for patients with WHO group 2–5 PH, mostly relying on hemodynamics and assessment of RV function to identify candidates for therapy. Clinical trials designed to test the efficacy of PAH therapy in PH due to left heart and lung disease are needed, as clinical practice has extended beyond the evidence for these etiologies of PH.Keywords
Funding Information
- National Institutes of Health (1P01HL108800‐01A1)
- National Center for Advancing Translational Sciences
This publication has 62 references indexed in Scilit:
- Pulmonary hypertension in chronic interstitial lung diseasesEuropean Respiratory Review, 2013
- Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary diseaseThe Journal of Heart and Lung Transplantation, 2012
- A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2010
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Association of the Metabolic Syndrome With Pulmonary Venous HypertensionChest, 2009
- Pulmonary Hypertension in Heart Failure With Preserved Ejection FractionJournal of the American College of Cardiology, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2008
- Cardiopulmonary Exercise Test Characteristics in Patients with Chronic Obstructive Pulmonary Disease and Associated Pulmonary HypertensionRespiration, 2007
- Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertensionHeart, 2006
- Venous and arterial changes in pulmonary veno-occlusive disease, mitral stenosis and fibrosing mediastinitisEuropean Respiratory Journal, 2000